Journal of Japan Society of Pain Clinicians
Online ISSN : 1884-1791
Print ISSN : 1340-4903
ISSN-L : 1340-4903
Search
Advanced search
OR
Browse
Search
Volume 29, Issue 6
Displaying 1-5 of 5 articles from this issue
Show all abstracts
    • |<
    • <
    • 1
    • >
    • >|
  • A case that observed respiratory depression after switching from tramadol to hydromorphone
    Keita KANAZAWA, Junko NOZATO, Shingo SATO, Momoko TAKAHASHI, Tetsuji I ...
    2022 Volume 29 Issue 6 Pages 119-122
    Published: June 25, 2022
    Released on J-STAGE: June 25, 2022
    DOIhttps://doi.org/10.11321/jjspc.21-0036
    JOURNAL FREE ACCESS FULL-TEXT HTML
    Show abstractHide abstract

    We report a case of hypopharyngeal cancer with a background of type II respiratory failure, who suffered from severe respiratory depression after hydromorphone was administered. The patient is a 77-year-old man, who was diagnosed with hypopharyngeal cancer and its distant metastases to left cervical lymph node, left scapula, lung, and liver. He was admitted to the palliative care unit for the purpose of relieving pain and dyspnea. After the introduction of oral sustained-release hydromorphone tablet (4 mg/day), significant respiratory depression was observed. After improvement of respiratory condition, respiratory depression was not observed since we avoided using opioids. In terminal patients with complications such as respiratory failure and hepatic or renal disorder, the dosage and administration route of hydromorphone have to be well-considered based on the patient's general condition and drug-metabolizing ability.

    View full abstract
    Download PDF (719K) Full view HTML
    • |<
    • <
    • 1
    • >
    • >|
feedback
 Top